Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Sonnet BioTherapeutics Holdings ( (SONN) ) has issued an announcement.
Sonnet BioTherapeutics Holdings, Inc., a biotech firm specializing in oncology, has met Nasdaq’s minimum bid price requirement, ensuring its continued listing on the Nasdaq Capital Market. Despite this achievement, the company will be monitored for a year to maintain compliance. Sonnet focuses on developing targeted biologic drugs and is currently advancing several promising programs for cancer treatment, including collaborations with industry giants like Roche.
Learn more about SONN stock on TipRanks’ Stock Analysis page.